Neil Versel

Aiforia offers a series of cancer-specific, CE-marked models and a DIY development platform for diagnostic and clinical decision support.

The privately held company is coupling gene expression tests with analysis to produce clinical decision support as it expands beyond its historic focus on pharma.

The Italian startup is expanding its eVai software platform to digenic rare disease diagnostics as it also broadens its marketing focus.

The molecular diagnostics and bioinformatics firm reduced its 2022 forecast as it reported a 23 percent year-over-year revenue decline in Q2.

The firm cited foreign currency weakness against the dollar in reducing its full-year estimate even as Q2 revenues grew 15 percent to $11.7 million.

The firm cited foreign currency weakness against the dollar in reducing its full-year estimate even as Q2 revenues grew 15 percent to $11.7M.

Although the firm remains in the red, the new CEO is counting on testing volume growth, health system partnerships, and operational efficiencies including layoffs to reach profitability.

The firm may draw additional revenues later this year from a forthcoming clinical decision support product.

The company formally introduced its SimpleTest 2 at HIMSS22 this week because the firm wants to play up the cloud-linked product's data management and interoperability features.

The purchase of GeneDx from Opko Health will help Sema4 accelerate its push into whole-exome sequencing and grow in rare disease diagnostics.